Phase 3 trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC)

被引：0

作者：

Cheng, A. -L. ^{[1
]}

Finn, R. S. ^{[2
]}

Qin, S. ^{[3
]}

Han, K. -H. ^{[4
]}

Ikeda, K. ^{[5
]}

Piscaglia, F. ^{[6
]}

Baron, A. ^{[7
]}

Park, J. -W. ^{[8
]}

Han, G. ^{[9
]}

Jassem, J. ^{[10
]}

Blanc, J. F. ^{[11
]}

Vogel, A. ^{[12
]}

Komov, D. ^{[13
]}

Evans, T. J. ^{[14
]}

Lopez, C. ^{[15
]}

Dutcus, C. ^{[16
]}

Ren, M. ^{[16
]}

Kraljevic, S. ^{[17
]}

Tamai, T. ^{[16
]}

Kudo, M. ^{[18
]}

机构：

[1] Natl Taiwan Univ Hosp, Taipei, Taiwan

[2] UCLA Med Ctr, Geffen Sch Med, Santa Monica, CA USA

[3] Nanjing Bayi Hosp, Nanjing, Jiangsu, Peoples R China

[4] Yonsei Univ, Severance Hosp, Seoul, South Korea

[5] Toranomon Gen Hosp, Tokyo, Japan

[6] Univ Bologna, Bologna, Italy

[7] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA

[8] Natl Canc Ctr Korea, Goyang Si, South Korea

[9] Fourth Mil Med Univ, Xijing Hosp, Xian, Shaanxi, Peoples R China

[10] Med Univ Gdansk, Gdansk, Poland

[11] Univ Bordeaux, Bordeaux, France

[12] Hannover Med Sch, Hannover, Germany

[13] NN Blokhin Canc Res Ctr, Moscow, Russia

[14] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[15] Marques de Valdecilla Univ Hosp, Santander, Spain

[16] Eisai Inc, Woodcliff Lake, NJ USA

[17] Eisai Ltd, Hatfield, PA USA

[18] Kindai Univ, Fac Med, Osaka, Japan

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2017年 / 40卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

'V720

引用

页码：211 / 211

页数：1

共 50 条

[31] Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan
Masahiro Kobayashi
Masatoshi Kudo
Namiki Izumi
Shuichi Kaneko
Mie Azuma
Ronda Copher
Genevieve Meier
Janice Pan
Mika Ishii
Shunya Ikeda
Journal of Gastroenterology, 2019, 54 : 558 - 570
[32] Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan
Kobayashi, Masahiro
Kudo, Masatoshi
Izumi, Namiki
Kaneko, Shuichi
Azuma, Mie
Copher, Ronda
Meier, Genevieve
Pan, Janice
Ishii, Mika
Ikeda, Shunya
JOURNAL OF GASTROENTEROLOGY, 2019, 54 (06) : 558 - 570
[33] Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma
Chen, Qiuping
Sun, Quan
Zhang, Jing
Li, Baixue
Feng, Quansheng
Liu, Jibin
PLOS ONE, 2024, 19 (03):
[34] Regorafenib plus nivolumab as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Multicenter phase 2 trial (RENOBATE)
Yoo, Changhoon
Ryoo, Baek-Yeol
Kim, Hyung-Don
Ryu, Min-Hee
Kang, Beodeul
Chon, Hong Jae
Hong, Jung Yong
Lim, Ho Yeong
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[35] Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)
Galle, Peter R.
Finn, Richard S.
Qin, Shukui
Ikeda, Masafumi
Zhu, Andrew X.
Kim, Tae-You
Kudo, Masatoshi
Breder, Valeriy Vladimirovich
Merle, Philippe
Kaseb, Ahmed Omar
Li, Daneng
Mulla, Sohail
Verret, Wendy
Xu, Derek-Zhen
Hernandez, Sairy
Liu, Juan
Huang, Chen
Lim, Ho Yeong
Cheng, Ann-Lii
Ducreux, Michel
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[36] A phase Ib study of lenvatinib plus pembrolizumab (LEN plus PEMBRO) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 116 follow-up analysis
Kudo, M.
Finn, R.
Ikeda, M.
Zhu, A.
Sung, M.
Baron, A.
Okusaka, T.
Kobayashi, M.
Kumada, H.
Kaneko, S.
Pracht, M.
Meyer, T.
Nagao, S.
Saito, K.
Mody, K.
Dubrovsky, L.
Llovet, J.
ANNALS OF ONCOLOGY, 2021, 32 : S1401 - S1402
[37] COST EFFECTIVENESS ANALYSIS OF LENVATINIB FOR THE FIRST-LINE TREATMENT OF INDIVIDUALS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA
Li, X.
Wudong, G.
Wang, Y.
VALUE IN HEALTH, 2020, 23 : S37 - S37
[38] A multicenter, observational, phase 4 study (STELLAR) to evaluate the safety and tolerability of lenvatinib (LEN) in patients with advanced or unresectable hepatocellular carcinoma (uHCC)
Peck-Radosavljevic, Markus
Goyal, Lipika
Strasser, Simone
Matilla Pena, Ana Maria
Marinho, Rui
Granito, Alessandro
Roderburg, Christoph
Marsico, Mark
Christou, Vanessa C.
Xie, Ran
Saraf, Pankhoori
Meyer, Tim
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[39] Characterization of tumor responses in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib in REFLECT.
Kudo, Masatoshi
Qin, Shukui
Piscaglia, Fabio
Vogel, Arndt
Evans, T. R. Jeffry
Knox, Jennifer J.
Lopez, Carlos Lopez
Ramji, Zahra
Ren, Min
Mody, Kalgi
Finn, Richard S.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[40] Health-related Quality of Life (HRQOL) and Disease Symptoms in Patients with Unresectable Hepatocellular Carcinoma (HCC) Treated with Lenvatinib (LEN) or Sorafenib (SOR)
Vogel, Arndt
Qin, Shukui
Kudo, Masatoshi
Hudgens, Stacie
Yamashita, Tatsuya
Yoon, Jung-Hwan
Fartoux, Laetitia
Simon, Krzysztof
Lopez, Carlos L.
Sung, Max
Dutcus, Corina E.
Kraljevic, Silvija
Tamai, Toshiyuki
Grunow, Nathan
Meier, Genevieve
Breder, Valeriy
HEPATOLOGY, 2017, 66 : 734A - 734A

← 1 2 3 4 5 →